European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028. What training is required for employees to handle HPAPIs safely?

Safety 89

Safety Pharmacology Training Manufacturing 89

European Pharmaceutical Review

NOVEMBER 1, 2023

It is one of the leading causes of death associated with AMR globally. Using this approach, our lead programme – RVX 001, a protein-based vaccine against invasive pneumococcal disease – has been designed with antigens common to all pneumococcus serotypes. AMR has the potential to be just as devastating for the world as COVID-19.

Safety 96

Safety Marketing Manufacturing Government 96

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

Marketing 59

Marketing Side effects Sales Safety 59

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

JUNE 27, 2022

According to the ClinicalTrials.gov trial registry, as of April 2022 3 there were 231 bsAbs in clinical trials and a recent industry report 4 predicts the global market revenue for these products will exceed $20 billion by 2028. Figure 1: Example of bi-specific formats. Tools such as the Lonza High?Throughput Nat Rev Drug Discov.

Recruitment 86

Recruitment Manufacturing Media Leads 86

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%). Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52